Price Action Don’t Lie: What’s Propelling Intellia Therapeutics Inc to Increase So Much?

Price Action Don't Lie: What's Propelling Intellia Therapeutics Inc to Increase So Much?

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 152,401 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.
The move comes after 7 months positive chart setup for the $748.32M company. It was reported on Nov, 16 by Barchart.com. We have $27.60 PT which if reached, will make NASDAQ:NTLA worth $359.19 million more.

Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage

Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The company was initiated on Tuesday, May 31 by Wedbush. Jefferies upgraded the stock to “Buy” rating in Friday, August 5 report. The rating was initiated by Jefferies on Tuesday, May 31 with “Hold”. The rating was upgraded by Leerink Swann to “Outperform” on Friday, August 5. Credit Suisse initiated it with “Outperform” rating and $39 target price in Tuesday, May 31 report.

According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More recent Intellia Therapeutics Inc (NASDAQ:NTLA) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on April 16, 2016. Also Bostonglobe.com published the news titled: “Space is at a premium for Cambridge startup Intellia” on October 27, 2016. Marketwatch.com‘s news article titled: “Intellia Therapeutics trading above issue price in market debut” with publication date: May 06, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment